Back to results
US 2020/0268654 A1Published application
Novel aerosol formulations of ondansetron and uses thereof
AssigneeLuxena Pharmaceuticals, Inc.
InventorsXiaodong LI, George LU, Biao LU
Life of this patent
Estimating the term…
Abstract
Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
Claims20
A dry powder aerosol formulation for use in a dry powder inhaler, comprising:
- ondansetron having a mean geometric diameter of between 1-3 microns;
- and a pharmaceutically acceptable excipient
- wherein the excipient is a mixture of coarse and fine particle lactose;
- and the coarse particle lactose has a D10 of about 3-6 μm, or a D90 of about 170 μm or has an average particle size of 50-200 μm;
- the fine particle lactose has a D50 of less than 5 μm;
- and
- the formulation has a respirable fraction (RPF) of 50% or more, when tested using a Next Generation Impactor (NGI).
4 more elements
Dependencies are inferred from the claim text.